HK1220358A1 - 減毒活甲病毒製劑的組合物和方法 - Google Patents

減毒活甲病毒製劑的組合物和方法

Info

Publication number
HK1220358A1
HK1220358A1 HK16108388.5A HK16108388A HK1220358A1 HK 1220358 A1 HK1220358 A1 HK 1220358A1 HK 16108388 A HK16108388 A HK 16108388A HK 1220358 A1 HK1220358 A1 HK 1220358A1
Authority
HK
Hong Kong
Prior art keywords
live
compositions
methods
attenuated alphavirus
formulations
Prior art date
Application number
HK16108388.5A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1220358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of HK1220358A1 publication Critical patent/HK1220358A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16108388.5A 2013-03-14 2016-07-15 減毒活甲病毒製劑的組合物和方法 HK1220358A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Publications (1)

Publication Number Publication Date
HK1220358A1 true HK1220358A1 (zh) 2017-05-05

Family

ID=50489420

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108388.5A HK1220358A1 (zh) 2013-03-14 2016-07-15 減毒活甲病毒製劑的組合物和方法

Country Status (20)

Country Link
US (2) US10137186B2 (zh)
EP (2) EP3603667A1 (zh)
JP (3) JP6426695B2 (zh)
KR (1) KR20160003662A (zh)
CN (2) CN111729077A (zh)
AP (1) AP2015008733A0 (zh)
AU (2) AU2014236804B2 (zh)
BR (1) BR112015023205A2 (zh)
CA (1) CA2903711A1 (zh)
CR (1) CR20150553A (zh)
DO (1) DOP2015000226A (zh)
EC (1) ECSP20007842A (zh)
HK (1) HK1220358A1 (zh)
MX (2) MX361342B (zh)
MY (1) MY178476A (zh)
NZ (1) NZ631012A (zh)
PH (1) PH12015502115A1 (zh)
SG (3) SG11201507462QA (zh)
TW (2) TW201900192A (zh)
WO (1) WO2014151855A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201900192A (zh) 2013-03-14 2019-01-01 美商武田疫苗股份有限公司 用於活減毒阿爾法病毒配方之組成物及方法
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
CA3019529A1 (en) * 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Compositions and methods for stabilizing alphaviruses with improved formulations
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
EP4282955A1 (en) * 2021-01-19 2023-11-29 Nitta Gelatin Inc. Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6458560B1 (en) * 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU5247199A (en) * 1998-07-30 2000-03-14 Johns Hopkins University School Of Medicine, The Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIO-ACTIVE MATERIALS WITH LYOPHILIZED FOAM
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
BRPI0716145B1 (pt) * 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
AR063606A1 (es) 2006-11-07 2009-02-04 Acambis Inc Estabilizacion de vacunas mediante liofilizacion
ES2621511T3 (es) 2007-04-06 2017-07-04 Takeda Vaccines, Inc. Métodos y composiciones para virus vivos atenuados
WO2009032913A2 (en) 2007-09-04 2009-03-12 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Thermal inactivation of rotavirus
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
EP2250269B1 (en) 2008-01-24 2016-03-16 The Board of Regents of The University of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
PL2376107T3 (pl) * 2008-12-09 2014-09-30 Coley Pharm Group Inc Oligonukleotydy immunostymulujące
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
PL2575873T3 (pl) * 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
TW201900192A (zh) * 2013-03-14 2019-01-01 美商武田疫苗股份有限公司 用於活減毒阿爾法病毒配方之組成物及方法

Also Published As

Publication number Publication date
AU2014236804A1 (en) 2015-10-01
PH12015502115B1 (en) 2016-01-25
PH12015502115A1 (en) 2016-01-25
MY178476A (en) 2020-10-14
BR112015023205A2 (pt) 2017-07-18
DOP2015000226A (es) 2016-02-29
WO2014151855A1 (en) 2014-09-25
CN111729077A (zh) 2020-10-02
AU2018236897A1 (en) 2018-10-18
EP2968515B1 (en) 2019-05-08
TWI649087B (zh) 2019-02-01
CN105377293A (zh) 2016-03-02
JP2020193231A (ja) 2020-12-03
MX2015012894A (es) 2016-04-04
ECSP20007842A (es) 2020-09-30
TW201900192A (zh) 2019-01-01
AP2015008733A0 (en) 2015-09-30
EP2968515A1 (en) 2016-01-20
MX2018014977A (es) 2022-06-27
SG10201909051QA (en) 2019-11-28
AU2014236804B2 (en) 2018-12-13
JP2019031543A (ja) 2019-02-28
SG11201507462QA (en) 2015-10-29
CR20150553A (es) 2015-12-01
US10806781B2 (en) 2020-10-20
JP6761015B2 (ja) 2020-09-23
NZ631012A (en) 2017-08-25
CN105377293B (zh) 2020-07-17
TW201513875A (zh) 2015-04-16
US20190134182A1 (en) 2019-05-09
EP3603667A1 (en) 2020-02-05
JP2016513658A (ja) 2016-05-16
JP6426695B2 (ja) 2018-11-21
US10137186B2 (en) 2018-11-27
US20140271715A1 (en) 2014-09-18
AU2018236897B2 (en) 2020-09-10
SG10201801459SA (en) 2018-03-28
KR20160003662A (ko) 2016-01-11
CA2903711A1 (en) 2014-09-25
MX361342B (es) 2018-12-04

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2520795B (en) Compositions and methods
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP3065716C0 (en) FORMULATIONS
ZA201505390B (en) Compositions and methods for treating pests
GB201308072D0 (en) Compositions and methods
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
SG11201506605XA (en) Ion implantation compositions, systems, and methods
GB201319792D0 (en) Formulations
IL266767A (en) Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter
EP2981529A4 (en) ORIDONIN ANALOGUES, COMPOSITIONS AND RELATED METHODS
HK1213800A1 (zh) 類毒素、組合物及相關方法
IL242795B (en) Preparations, methods and devices for dialysis
EP2953455A4 (en) ANTIMICROBIAL COMPOSITIONS, WIPES AND METHODS
GB201305813D0 (en) Compositions and methods
HK1220358A1 (zh) 減毒活甲病毒製劑的組合物和方法
IL243778A0 (en) Combined immune complexes
HK1214951A1 (zh) 眼用製劑
PT3066199T (pt) Snorna, composições e utilizações
HK1213917A1 (zh) 類霉素、組合物及相關方法
HK1212916A1 (zh) 包含炮製提取物的組合物
GB201313990D0 (en) Combination immunogenic compositions
GB201322617D0 (en) Methods and compositions